Biogen Inc. (NASDAQ:BIIB) Stock Has Consensus Price Target of $231.07 According to Analysts

Key Points

• Biogen has a “Moderate Buy” consensus rating from 32 analysts, with 17 buy ratings, 13 holds, one sell and one strong buy. The average 12-month price target is $231.07.
• Institutional investors own 87.93% of Biogen’s outstanding stock, while the shares recently opened at $225.71, near the consensus target and their 52-week high of $230.49.
• Biogen reported quarterly EPS of $3.60, beating estimates of $2.94, while revenue of $2.74 billion exceeded forecasts of $2.46 billion and increased 3.4% year over year.

Shares of Biogen Inc. (NASDAQ:BIIB - Get Free Report) have earned a consensus rating of "Moderate Buy" from the thirty-two analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $231.07.

BIIB has been the subject of several analyst reports. Morgan Stanley raised their price target on shares of Biogen from $222.00 to $231.00 and gave the company an "equal weight" rating in a research note on Thursday, July 30th. Piper Sandler restated an "overweight" rating and issued a $245.00 price objective (up from $225.00) on shares of Biogen in a report on Thursday, September 3rd. Oppenheimer reaffirmed an "outperform" rating and set a $300.00 target price on shares of Biogen in a research report on Wednesday, July 29th. Weiss Ratings raised Biogen from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, September 24th. Finally, Needham & Company LLC lifted their target price on Biogen from $255.00 to $256.00 and gave the stock a "buy" rating in a report on Monday, June 29th.

Institutional Investors Weigh In On Biogen

A number of hedge funds have recently added to or reduced their stakes in the business. Reflection Asset Management acquired a new position in Biogen during the fourth quarter worth $25,000. Bell Investment Advisors Inc bought a new position in shares of Biogen in the second quarter valued at $27,000. MV Capital Management Inc. acquired a new position in shares of Biogen during the fourth quarter valued at about $34,000. SHP Wealth Management acquired a new position in shares of Biogen during the fourth quarter valued at about $39,000. Finally, Cassaday & Co Wealth Management LLC bought a new stake in shares of Biogen during the first quarter worth about $40,000. 87.93% of the stock is currently owned by institutional investors.

Biogen Stock Performance

NASDAQ:BIIB opened at $225.71 on Friday. The stock's 50-day moving average is $217.41 and its 200-day moving average is $202.26. Biogen has a 1-year low of $138.00 and a 1-year high of $230.49. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The stock has a market cap of $33.35 billion, a P/E ratio of 39.95, a price-to-earnings-growth ratio of 2.41 and a beta of 0.09.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The business had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.46 billion. During the same quarter last year, the business earned $5.47 EPS. The firm's quarterly revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities research analysts anticipate that Biogen will post 12.41 earnings per share for the current year.

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen's products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich's ataxia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.